Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II

Frontiers in Oncology

Oncology

Nirmish Singla¹  Tsung-Mu Yang²  Hsin-Chih Yeh³  Chung-Hsin Chen⁴  Jer-Tsong Hsieh⁵ 

[1] Brady Urological Institute, School of Medicine, Johns Hopkins Medicine, Baltimore, MD, United States;Department of General Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Urology, National Taiwan University Hospital, Taipei, Taiwan;Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States;

关键词: upper tract urothelial carcinoma;    precision oncology;    surgical wait time;    nomogram;    immunochemotherapy;    CCAAT/enhancer-binding protein delta;   

DOI  :  10.3389/fonc.2023.1276718

 received in 2023-08-12, accepted in 2023-08-21,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Yang, Singla, Chen, Hsieh and Yeh